Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause

 | Apr 14, 2021 23:04

Yesterday, the US Food and Drug Administration halted the use of Johnson & Johnson's (NYSE:JNJ) one-shot coronavirus vaccine when a rare blood-clotting disorder developed in six women between the ages of 18-48 and one died. After the announcement, Moderna (NASDAQ:MRNA) quickly, and appropriately, defended its own vaccine, which the company pointed out, uses a different technology.

While the FDA was careful in its language, calling the stop a “pause,” it could create a serious setback for the Biden administration's ongoing efforts to ramp-up vaccination efforts across the country as inoculation supplies will likely diminish, at least in the short run. In addition, this setback could convince people already uneasy about the vaccines to decide not to vaccinate at all.

After the J&J news broke, some of that changed. Markets beat up on JNJ and AstraZeneca (NASDAQ:AZN), whose vaccine is also causing worrying side effects in a small number of recipients. Shares of both pharmaceutical companies dropped yesterday on Wall Street.

Ironically, we wrote about Pfizer (NYSE:PFE) on Tuesday for this column, before the JNJ pause was announced. In our view at the time, Pfizer's fundamental and Moderna's technical outlook were the strongest among its vaccine competitors.

Conversely, Moderna surged, outperforming all competitors, to gain 7.4%. The upside looks like it might just be getting started too.